News|Articles|September 10, 2013

McNeil Recalls Motrin Drops After Plastic is Found in Ingredient

McNeil Consumer Healthcare Division of McNeil-PPC announced a voluntary recall of three lots of Motrin Infants? Drops after 1 mm plastic particles were identified in a different product lot during manufacturing.

McNeil Consumer Healthcare Division of McNeil-PPC announced on Sept. 6 a voluntary recall at the retail level of three lots of Concentrated Motrin Infants’ Drops Original Berry Flavor (0.5 fl oz bottles) after 1 mm plastic particles were identified in a different product lot during manufacturing.  The lot in which the particles were discovered was not released to the market.

In a press statement posted on www.FDA.gov and the McNeil website, the company reported that the particles originated in a shipment from a third-party supplier of ibuprofen, the active ingredient in the recalled product.  The company said that, out of an abundance of caution, it was recalling the three lots—approximately 200,000 bottles distributed in the United States—that were made with the same batch of active ingredient.  

The company says it has worked with the third party to ensure that corrective measures are currently in place and the potential for adverse medical events related to the reason for this recall is not likely.   

McNeil is asking retailers to remove the affected lots from store shelves and is asking consumers to stop using and dispose of any product they may have that is included in this recall.

Sources: FDA and McNeil Consumer Healthcare Division of McNeil-PPC

 


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.